Nan Lan1, Bo Shen1. 1. Interventional Inflammatory Bowel Disease (i-IBD) Unit, Digestive Disease and Surgery Institute, the Cleveland Clinic Foundation, Cleveland, Ohio.
Abstract
Background: Current treatment modalities for anastomotic stricture in Crohn's disease (CD) include endoscopic balloon dilation (EBD) and surgery. We recently published a case series of inflammatory bowel disease patients treated with the novel endoscopic stricturotomy (ES). The aim of this case-control study was to compare the efficacy and safety of ES versus conventional EBD in the treatment of anastomotic strictures in CD patients. Methods: All eligible patients with CD anastomotic stricture who were treated with ES or EBD were included. The primary outcomes were surgery-free survival and post-procedural complications. Results: A total of 185 patients were studied, including 21 treated with ES since 2009, and 164 treated with EBD since 1998. The immediate technical success after therapy was achieved in 100% of patients treated with ES and 89.5% of patients with EBD. Symptomatic and endoscopic improvement rates were higher in those treated with ES than EBD. Subsequent surgery was needed in 2 (9.5%) patients with ES and 55 (33.5%) with EBD (P = 0.03), during a median of 0.8 (interquartile range [IQR]:0.1-1.6) year and 4.0 (IQR: 0.8-6.9) years, respectively. Five procedure-associated perforation (1.1% per procedure) occurred in the EBD group and none in the ES group. In contrast, 4 procedure-associated, transfusion-required bleeding (8.8% per procedure) occurred in the ES group and none in the EBD group. Conclusions: ES appears to be more effective in treating CD patients with anastomotic stricture than EBD. Although ES may have a lower risk for perforation, the procedure needs to be perfected to reduce its bleeding risk.
Background: Current treatment modalities for anastomotic stricture in Crohn's disease (CD) include endoscopic balloon dilation (EBD) and surgery. We recently published a case series of inflammatory bowel diseasepatients treated with the novel endoscopic stricturotomy (ES). The aim of this case-control study was to compare the efficacy and safety of ES versus conventional EBD in the treatment of anastomotic strictures in CDpatients. Methods: All eligible patients with CD anastomotic stricture who were treated with ES or EBD were included. The primary outcomes were surgery-free survival and post-procedural complications. Results: A total of 185 patients were studied, including 21 treated with ES since 2009, and 164 treated with EBD since 1998. The immediate technical success after therapy was achieved in 100% of patients treated with ES and 89.5% of patients with EBD. Symptomatic and endoscopic improvement rates were higher in those treated with ES than EBD. Subsequent surgery was needed in 2 (9.5%) patients with ES and 55 (33.5%) with EBD (P = 0.03), during a median of 0.8 (interquartile range [IQR]:0.1-1.6) year and 4.0 (IQR: 0.8-6.9) years, respectively. Five procedure-associated perforation (1.1% per procedure) occurred in the EBD group and none in the ES group. In contrast, 4 procedure-associated, transfusion-required bleeding (8.8% per procedure) occurred in the ES group and none in the EBD group. Conclusions: ES appears to be more effective in treating CDpatients with anastomotic stricture than EBD. Although ES may have a lower risk for perforation, the procedure needs to be perfected to reduce its bleeding risk.
Authors: G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi Journal: Tech Coloproctol Date: 2020-03-14 Impact factor: 3.781
Authors: Fotios S Fousekis; Ioannis V Mitselos; Kostas Tepelenis; George Pappas-Gogos; Konstantinos H Katsanos; Georgios D Lianos; Francesco Frattini; Konstantinos Vlachos; Dimitrios K Christodoulou Journal: J Clin Med Date: 2022-04-23 Impact factor: 4.964
Authors: Belinda De Simone; Justin Davies; Elie Chouillard; Salomone Di Saverio; Frank Hoentjen; Antonio Tarasconi; Massimo Sartelli; Walter L Biffl; Luca Ansaloni; Federico Coccolini; Massimo Chiarugi; Nicola De'Angelis; Ernest E Moore; Yoram Kluger; Fikri Abu-Zidan; Boris Sakakushev; Raul Coimbra; Valerio Celentano; Imtiaz Wani; Tadeja Pintar; Gabriele Sganga; Isidoro Di Carlo; Dario Tartaglia; Manos Pikoulis; Maurizio Cardi; Marc A De Moya; Ari Leppaniemi; Andrew Kirkpatrick; Vanni Agnoletti; Gilberto Poggioli; Paolo Carcoforo; Gian Luca Baiocchi; Fausto Catena Journal: World J Emerg Surg Date: 2021-05-11 Impact factor: 5.469
Authors: Andrew M Veitch; Franco Radaelli; Raza Alikhan; Jean-Marc Dumonceau; Diane Eaton; Jo Jerrome; Will Lester; David Nylander; Mo Thoufeeq; Geoffroy Vanbiervliet; James R Wilkinson; Jeanin E van Hooft Journal: Endoscopy Date: 2021-08-06 Impact factor: 10.093
Authors: Andrew M Veitch; Franco Radaelli; Raza Alikhan; Jean Marc Dumonceau; Diane Eaton; Jo Jerrome; Will Lester; David Nylander; Mo Thoufeeq; Geoffroy Vanbiervliet; James R Wilkinson; Jeanin E Van Hooft Journal: Gut Date: 2021-09 Impact factor: 23.059